Steffen Ruchholtz

Prof. Dr. Steffen Ruchholtz

Center for Orthopedics and Trauma Surgery, University Hospital of Marburg, Marburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Medicina
Verified
Journal Article
Open access
PDF file
RARene Aigner
Rene Aigner
BBBenjamin Buecking
Benjamin Buecking
JHJuliana Hack
Juliana Hack
RSRuth Schwenzfeur
Ruth Schwenzfeur
DEDaphne-Asimenia Eschbach
Daphne-Asimenia Eschbach
O(On Behalf Of The Registry For Geriatric Trauma (Atr-Dgu)
On Behalf Of The Registry For Geriatric Trauma (Atr-Dgu)
Background and Objectives: The increased use of direct oral anticoagulants (DOACs) results in an increased prevalence of DOAC treatment in hip fractures patients. However, the impact of DOAC treatment on perioperative management of hip fracture patients is limited. In this study, we describe the prevalence of DOAC treatment in a population of hip fracture patients and compare these patients with patients taking vitamin K antagonists (VKA) and patients not taking anticoagulants. Materials and Methods: This study is a retrospective analysis from the Registry for Geriatric Trauma (ATR-DGU). The data were collected prospectively from patients with proximal femur fractures treated between January 2016 and December 2018. Among other factors, anticoagulation was surveyed. The primary outcome parameter was time-to-surgery. Further parameters were: type of anesthesia, surgical complications, soft tissue complications, length of stay and mortality. Results: In total, 11% (n = 1595) of patients took DOACs at the time of fracture, whereas 9.2% (n = 1325) were on VKA therapy. During the study period, there was a shift from VKA to DOACs. The time-to-surgery of patients on DOACs and of patients on VKA was longer compared to patients who did not take any anticoagulation. No significant differences with regard to complications, type of anesthesia and mortality were found between patients on DOACs compared to VKA treatment. Conclusion: An increased time-to-surgery in patients taking DOACs and taking VKA compared to non-anticoagulated patients was found. This underlines the need for standardized multi-disciplinary orthopedic, hematologic and ortho-geriatric algorithms for the management of hip fracture patients under DOAC treatment. In addition, no significant differences regarding complications and mortality were found between DOAC and VKA users. This demonstrates that even in the absence of widely available antidotes, the safe management of geriatric patients under DOACs with proximal femur fractures is possible.

4 July 2024 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LHLaura Heuser
Laura Heuser
CSCarsten Schoeneberg
Carsten Schoeneberg
KRKatherine Rascher
Katherine Rascher
SLSven Lendemans
Sven Lendemans
MKMatthias Knobe
Matthias Knobe
O(On Behalf Of The Registry For Geriatric Trauma (Atr-Dgu)
On Behalf Of The Registry For Geriatric Trauma (Atr-Dgu)

26 August 2022 in Die Unfallchirurgie
Verified
Journal Article
Closed access
PDF file
SRSteffen Ruchholtz
Steffen Ruchholtz

3 April 2026 in Cancer Genetics
Verified
Journal Article
Open access
NHNuwar Harb
Nuwar Harb
MRMarcel Romey
Marcel Romey
AGAlbert Grass
Albert Grass
FKFlorentin von Kügelgen
Florentin von Kügelgen
AHAkira Hattesohl
Akira Hattesohl
JTJulia Teply-Szymanski
Julia Teply-Szymanski
Personalized medicine is guided by an expanding array of molecular targets. This study investigates whether larger next-generation sequencing (NGS) gene panels (> 1 Mb) yield more clinically relevant therapy options in molecular tumor boards (MTB) compared to smaller panels. We analyzed 281 consecutive patients using a 430-gene DNA panel (1.3 Mb) combined with a RNA-fusion panel and compared the findings to a 185-gene DNA panel (618 kb). Molecular alterations were detected in 97.2 % of tumors with either oncogenic variants and/or gene fusions. Among these, 170 (60.5 %) received a molecular-stratified therapy recommendation from the local MTB. Only 8.8 % depended on the expanded 430-gene DNA panel, and additionally identified actionable variants in five additional genes. High TMB alone enabled 4.1 % of MTB recommendations. Our findings indicate that sufficient genomic coverage in DNA panels is essential for reliable TMB calculation, defining a minimal standard for genomic cancer care.

19 August 2026 in Injury
Verified
Journal Article
Closed access
BPBastian Pass
Bastian Pass
ABA. Boerner
A. Boerner
Juliana Franziska BouschJuliana Franziska Bousch
Juliana Franziska Bousch
DSD. Schoeps
D. Schoeps
UMUwe Maus
Uwe Maus
CSCarsten Schoeneberg
Carsten Schoeneberg